AbbVie Inc. $ABBV Shares Purchased by JB Capital LLC

JB Capital LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 269.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,913 shares of the company’s stock after acquiring an additional 12,338 shares during the quarter. JB Capital LLC’s holdings in AbbVie were worth $3,864,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of ABBV. Diversified Trust Co boosted its position in AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after buying an additional 10,891 shares during the period. Permanent Capital Management LP purchased a new stake in shares of AbbVie during the third quarter worth $720,000. Railway Pension Investments Ltd raised its stake in shares of AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after acquiring an additional 211,800 shares in the last quarter. World Investment Advisors raised its stake in shares of AbbVie by 9.4% in the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after acquiring an additional 9,811 shares in the last quarter. Finally, Charles Schwab Trust Co boosted its holdings in AbbVie by 93.4% in the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after purchasing an additional 15,502 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Price Performance

Shares of NYSE ABBV opened at $208.79 on Friday. The business has a 50-day moving average of $221.58 and a two-hundred day moving average of $224.47. The company has a market capitalization of $369.17 billion, a price-to-earnings ratio of 88.47, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Insider Buying and Selling

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ABBV shares. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Morgan Stanley lifted their price target on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Evercore lowered their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.